1️⃣ Makary’s exit turns FDA timing into personnel risk Marty Makary is resigning as FDA commissioner after 13 months, with Kyle Diamantas expected to take over in an acting role.
💡 Why it matters Sponsors now have to price review risk around leadership churn, center vacancies and political pressure at the same time.
☕ Coffee talk Which PDUFA dates now need a personnel-risk line in the IC memo?
2️⃣ Europe made shortages an industrial-policy problem EMA welcomed a provisional Critical Medicines Act deal that ties shortages to vulnerability assessments, strategic projects and public procurement.
💡 Why it matters For APIs, generics and CDMOs, supply resilience is moving from health-ministry plumbing into investable market structure.
☕ Coffee talk Who owns the boring European capacity that suddenly looks strategic?
3️⃣ UK medtech reliance gets a draft rulebook MHRA published draft GB pre-market rules for devices and IVDs, including faster access for products approved in Australia, Canada or the U.S.
💡 Why it matters The UK is trying to buy speed with reliance while adding UDI, implant-card and IVD classification requirements.
☕ Coffee talk How many device models can use that shortcut without rebuilding the file?